Wanbury has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs). For Diphenhydramine HCl, the company has submitted DMF to Malaysia and Singapore. The company has proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. The company has also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1787.10 |
| Dr. Reddys Lab | 1271.75 |
| Cipla | 1376.25 |
| Zydus Lifesciences | 1097.90 |
| Lupin | 2248.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: